Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Names New Distribution Partners

NEW YORK (GenomeWeb) – Rubicon Genomics today said that it has signed distribution deals with new partners covering parts of Europe, North Africa, and Asia, further expanding the market reach for its DNA library preparation kits for arrays and Illumina next-generation sequencing platforms.

The new distributors are CliniSciences in France, Spain, and North Africa; Nerliens Meszansky covering Norway; Shanghai Nanodigmnio Biotechnology in China; and GeneLabs Life Science serving customers in Taiwan. Products covered under the deals include Rubicon's ThruPLEX DNA-seq, PicoPLEX DNA-seq, and PicoPLEX WGA Kits.

"Our strategy of expanding our global network of distributors is working well — product sales of our DNA library prep kits are up more than 50 percent in the first nine months of 2014 compared to the same period in 2013," Rubicon Genomics CEO James Koziarz said in a statement.

Terms of the distribution deals were not disclosed.

The Ann Arbor, Mich.-based firm also said that it has appointed Karl Hecker as its new VP of product development. Hecker previously held product development positions at Invitrogen, PerkinElmer, Transgenomic, Quidel, and HTG Molecular Diagnostics.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.